Pharma PLI scheme has export generation potential of Rs 1.96 tn: Mandaviya

PLI for pharmaceutical products has export generation potential of Rs 1,96,000 crore over a period of six years, Parliament was informed on Tuesday.

Mansukh Mandaviya, Health Minister
Mansukh Mandaviya, Union Health Minister
Press Trust of India New Delhi
2 min read Last Updated : Jul 27 2021 | 9:44 PM IST

The production linked incentive scheme (PLI) for pharmaceutical products has export generation potential of Rs 1,96,000 crore over a period of six years, Parliament was informed on Tuesday.

The government had approved the PLI scheme for pharmaceuticals on February 24 this year.

"The scheme estimated the export generation potential of Rs 1,96,000 crore over a period of six years in all the three categories of products under the scheme, which includes high-value products as well," Chemicals and Fertilisers Minister Mansukh Mandaviya said in a written reply to the Lok Sabha.

The PLI scheme estimated the investment potential of around Rs 15,000 crore and the generation of the employment potential of 20,000 direct and 80,000 indirect jobs as a result of the growth in the sector over the period of the scheme, he added.

The minister noted that currently, low-value generic drugs account for the major component of Indian exports.

The scheme incentivises the manufacturing of patented drugs and other high-value drugs at an incentive rate of 10 per cent of incremental sales, which is the highest among the product categories under the scheme, he added.

On June 1 this year, the government had issued operational guidelines for the PLI scheme for the pharmaceutical industry to enhance India's manufacturing capabilities by increasing investment and production in the sector.

Earlier, the Department of Pharmaceuticals had notified the scheme with an outlay of Rs 15,000 crore.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Pharma sectorPLI schemeMansukh Lal Mandaviya

First Published: Jul 27 2021 | 9:44 PM IST

Next Story